#puberty-blockers

#puberty-blockers

However, the 2024 Cass review of NHS gender identity services for children and young people found there was insufficient/inconsistent evidence about the effects of puberty suppression on psychological or psychosocial wellbeing, cognitive development, cardio-metabolic risk or fertility. NHS England subsequently announced children with gender dysphoria would no longer receive puberty blockers as routine practice, with their use confined to research settings.

It follows the banning of the drugs for gender treatment last year after a major review raised concerns about the lack of clinical evidence over their safety for under-18s. Researchers from King's College London say the trial will involve around 220 children under the age of 16 who are going through puberty, and will examine the impact of the drugs on their physical, social and emotional wellbeing.

"I remember working with Esme Wren and Hannah Barnes and Deb Cohen and we were looking at the question of the Tavistock," she said. "This was the only gender identity development service for the under-16s. "We questioned why it wasn't data led, why it seemed to be so arbitrary with the kind of recommendations and advice and even the [puberty] blockers they were handing out to young people. "The work we did actually led to the closure of the Tavistock."

NHS patients who are already receiving these medicines for gender incongruence and/or gender dysphoria can continue to access them, as can patients receiving the medicines for other uses.

The court heard that health director-general Dr David Rosengren had consulted with executives of the state's hospitals and health services at 10am on 28 January, the same time that Nicholls held a press conference announcing the ban and a subsequent review. In a statement to parliament on Tuesday, just hours after the verdict, Nicholls issued a "written ministerial direction" to reinstate the ban until the review had been completed, saying the court ruling had focused on the improper process behind the ban's enactment, not whether it was appropriate. 'I am satisfied it is appropriate and in the public interest that I issue a written ministerial direction,' he said, according to The Guardian. The new directive's provisions are believed to match those announced in January.

Queensland's controversial ban on puberty blockers and other hormone therapies is unlawful because of a failure to properly consult health executives on a decision affected by political interference, a court has heard. The supreme court in Brisbane on Wednesday heard the ban should be overturned as part of a legal challenge launched by the mother of a transgender child. The mother cannot be identified for legal reasons.

A Supreme Court judge has reserved his decision on a legal challenge against Queensland's refusal to provide trans youth healthcare. Supreme Court Justice Peter Callaghan reserved his judgement in the case brought by the mother of a trans teen who was denied puberty blockers as a result of the government's decision. The Australian state chose to restrict puberty blocker prescriptions for trans youth in January as part of a review into the hormone suppressants.

"I am extremely frustrated by the slow progress on the clinical trial. The reason it's taking its time is because it is absolutely vital that we get the research programme right, so that at the end of that programme, the evidence can be trusted and not subject to challenge."